Long-Term Follow-Up Results From the MURANO Trial in CLL
Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.
Nicole Lamanna, MD, associate professor and CLL director at the Columbia University Irving Medical Center, discusses the significance of the 3-year follow-up data for the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Patients had a progression-free survival (PFS) rate of 71% with a fixed duration of venetoclax (Venclexta) plus rituximab (Rituxan), compared to about 17% with bendamustine plus rituximab.
All patients had stopped venetoclax treatment at 2 years; these data were also broken down based on minimal residual disease (MRD) for further follow-up. In this analysis, Lamanna says there was a significant correlation between those who had undetectable disease and those who did very well.
